Group Pierre Ã…man
Short description
Research on FET fusion oncoproteins and FET-SWI/SNF interactions.
Research summary
Chromosome rearrangements that lead to formation of fusion oncogenes have been identified in many types of leukemia and solid tumors. The FET-group of fusion oncogenes encode chimeric transcription factor proteins containing N-terminal parts of FET proteins juxtaposed to C-terminal DNA binding transcription factor parts.
We have recently found that all FET-oncoproteins bind and change the activities of the SWI/SNF chromatin remodeling complex. Deregulation of SWI/SNF activity thus provides a unifying pathogenic mechanism for the large group of tumors caused by FET fusion oncoproteins.
Our research focus on the FET-SWI/SNF interactions and its consequences on molecular and cellular levels. Drug tests are also performed in vitro and in vivo and based on findings from our experimental systems.
Research tools and resources
Experimental systems: tumor cell lines, and xenograft models.
Methods: protein–protein interaction studies using recombinant proteins and immunoprecitpitation/mass spectometry. Chromatin immunoprecipitation (ChIP-seq), advanced microscopy, and single cell expression analysis.
Experimental findings are confirmed with studies on human tumor tissues.
Current group members
Pierre Ã…man, PhD, Professor
Mikael Kubista, Researcher
Christoffer Vannas, PhD student
Selected publications
Lindén M, Thomsen C, Grundevik P, Jonasson E, Andersson D, Runnberg R, Dolatabadi S, Vannas C, Luna Santamarίa M, Fagman H, Ståhlberg A, Åman P. EMBO Rep. (2019) Apr 8. pii: e45766. doi: 10.15252/embr.201845766.
Trautmann M, Cyra M, Isfort I, Jeiler B, Kruger A, Grunewald I, Steinestel K, Altvater B, Rossig C, Hafner S, et al. (2019) Molecular cancer therapeutics, 10.1158/1535-7163.MCT-18-0763
Dolatabadi S, Jonasson E, Linden M, Fereydouni B, Backsten K, Nilsson M, Martner A, Forootan A, Fagman H, Landberg G, et al. (2019) Int J Cancer, 10.1002/ijc.32123
Svec D, Dolatabadi S, Thomsen C, Cordes N, Shannon M, Fitzpatrick P, Landberg G, Aman P, Stahlberg A (2018) Lab Invest 98: 957-967
Trautmann M, Menzel J, Bertling C, Cyra M, Isfort I, Steinestel K, Elges S, Grunewald I, Altvater B, Rossig C, et al. (2017) Clin Cancer Res 23: 6227-6238
Tomic TT, Olausson J, Wilzen A, Sabel M, Truve K, Sjogren H, Dosa S, Tisell M, Lannering B, Enlund F, et al. (2017) PLoS One 12: e0175638
Dolatabadi S, Candia J, Akrap N, Vannas C, Tesan Tomic T, Losert W, Landberg G, Aman P, Stahlberg A (2017) Front Genet 8:1
Safavi S, Jarnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, et al. (2016) Oncotarget 7: 433-445
de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, Aman P, Torres KE, et al. (2016) Lab Invest 96: 885-894
Angelika Ihle M, Merkelbach-Bruse S, Hartmann W, Bauer S, Ratner N, Sonobe H, Nishio J, Larsson O, Aman P, Pedeutour F, et al. (2016) J Pathol Clin Res 2: 59-71
91̽»¨ information
Pierre Ã…man
E-mail: Pierre Ã…man
Phone: +46 (0)31 786 6732
Visiting address:
Sahlgrenska Center
for Cancer Research,
Medicinaregatan 1F
413 90 Gothenburg
Research presentation
Summary of ongoing research about novel interventions for patients diagnosed with FET sarcomas.
In collaboration with Professor Anders Ståhlberg.
